Immune checkpoint inhibitor

Open Access
HLA Class I Loss and Resistance to Immunotherapy in Pulmonary Metastasis of Hypopharyngeal Cancer
AKIRA MURAKAMI, KAORI YUKINO, YOSHIHIRO KOMOHARA, YU SHIMODA, HARUKI SAITO, YUKIO FUJIWARA and YORIHISA ORITA

In Vivo May 2026, 40 (3) 1753-1759; DOI: https://doi.org/10.21873/invivo.14327
Open Access
Drug-induced Aseptic Meningitis: Pharmacovigilance Analysis of Japanese Adverse Event Reporting Database
SHO MASAGO, KAZUMASA KOTAKE, KENTA YAMAOKA, KENNOSUKE YORIFUJI and TADASHI SHIMIZU

In Vivo March 2026, 40 (2) 1220-1227; DOI: https://doi.org/10.21873/invivo.14277
Open Access
Comparative Analysis of Immune-based Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma
YUTA MUKAE, KOJIRO OHBA, HIROMI NAKANISHI, MASAHARU OKI, KEN KAWADA, TSUYOSHI MATSUDA, KENSUKE MITSUNARI, TOMOHIRO MATSUO, YASUSHI MOCHIZUKI and RYOICHI IMAMURA

In Vivo January 2026, 40 (1) 389-397; DOI: https://doi.org/10.21873/invivo.14203
Open Access
Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma
MASAHARU OKI, KOJIRO OHBA, YUTA MUKAE, TSUYOSHI MATSUDA, HIROMI NAKANISHI, KENSUKE MITSUNARI, TOMOHIRO MATSUO, YASUSHI MOCHIZUKI and RYOICHI IMAMURA

In Vivo November 2025, 39 (6) 3445-3452; DOI: https://doi.org/10.21873/invivo.14142
Open Access
Long-term Outcomes and Mixed Response in Nivolumab Therapy for Head and Neck Cancer
YOH-ICHIRO IWASA, RYOSUKE KITOH, YOH YOKOTA, KENTARO HORI, MARIKO KASUGA, SHINTARO YAMAZAKI and YUTAKA TAKUMI

In Vivo September 2025, 39 (5) 2777-2786; DOI: https://doi.org/10.21873/invivo.14076
Open Access
Conversion Surgery Performed Following Durvalumab Combined With Gemcitabine and Cisplatin in Cholangiocarcinoma: A Case Report
YOSHIYUKI TAGAYASU, RIN YAMADA, KOSUKE KANEMITSU, YOSHIHIKO KONDO, RUMI ITOYAMA, HIROMITSU HAYASHI, YOSHIHIRO KOMOHARA and MASAAKI IWATSUKI

In Vivo May 2025, 39 (3) 1724-1730; DOI: https://doi.org/10.21873/invivo.13974
Open Access
A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy
MINEHIKO INOMATA, DAISUKE FURUKAWA, NAOKI TAKATA, KOTARO TOKUI, SEISUKE OKAZAWA, SHINGO IMANISHI and SATOSHI NOMURA

In Vivo March 2025, 39 (2) 1207-1210; DOI: https://doi.org/10.21873/invivo.13925
Open Access
Nivolumab Rechallenge After Immune-related Adverse Events in Patients With Unresectable Advanced or Recurrent Esophageal Cancer
KOHDAI UENO, KUNIHITO SUZUKI, KATSUMASA SAITO, HAJIME SHINOHARA and AKINORI MIURA

In Vivo March 2024, 38 (2) 794-799; DOI: https://doi.org/10.21873/invivo.13503
Open Access
Utility of Precision Oncology Using Cancer Genomic Profiling for Head and Neck Malignancies
MIOKO MATSUO, KAZUKI HASHIMOTO, RYUNOSUKE KOGO, RINA JIROMARU, TAKAHIRO HONGO, TOMOMI MANAKO and TAKASHI NAKAGAWA

In Vivo September 2023, 37 (5) 2147-2154; DOI: https://doi.org/10.21873/invivo.13312
Open Access
Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
TOMOMI MANAKO, RYUJI YASUMATSU, TAKAFUMI NAKANO, MIOKO MATSUO, TORANOSHIN TAKEUCHI, MASAHIKO TAURA, AKIHIRO TAMAE, MORIYASU YAMAUCHI, MUNEYUKI MASUDA, KENICHI TAGUCHI and TAKASHI NAKAGAWA

In Vivo March 2023, 37 (2) 747-755; DOI: https://doi.org/10.21873/invivo.13137

Main menu

User menu

Search

Immune checkpoint inhibitor

Pages